# Trust in the FDA is eroding: Transparency in food and drugs is imperative

How scientific integrity and predictability can restore the FDA's credibility

- **Source:** [Fortune | FORTUNE](https://brifing.si/source/769282ef-327a-4454-909a-3c7936216004)
- **Published:** 2026-07-14
- **Topic:** [Business](https://brifing.si/c/business)
- **Original article:** <https://fortune.com/2026/07/14/fda-trust-decline-political-interference-rfk/>
- **On Brifing:** https://brifing.si/s/679ca134-fb06-4650-b17e-c8f978c1c935

## FDA's unique role

The FDA sits at the critical intersection of science, medicine, and public health. Patients rely on therapy evaluations, innovators need predictable pathways, and investors trust evidence-based decisions. But recent inconsistencies have shaken this trust.

## Impact of eroding trust

From rare disease therapies to Moderna's mRNA vaccine, FDA's abrupt policy shifts have impacted entire innovation ecosystems. Companies now complain about unpredictable decision-making processes that create business uncertainty.

## Scientific integrity questioned

FDA's deviation from evidence-based decision-making in recent years has alarmed the scientific community. Rare disease advocates emphasize that consistency is vital when patients have no alternative treatment options.

## The Replimune case

Replimune's metastatic melanoma treatment highlights FDA's alleged shifting evidence expectations. Similar issues emerged with Huntington's disease and Hunter syndrome therapies. These cases raise questions about consistent standard application.

## Real-world evidence gap

Critics argue FDA undervalues real-world evidence and expert input, particularly crucial for rare diseases where clinical trial data is limited. This oversight creates approval bottlenecks for life-saving treatments.

## Cost of regulatory uncertainty

FDA's delayed or reversed decisions jeopardize pharma companies' multi-year research and million-dollar investments. This uncertainty slows innovation and ultimately delays patient access to critical therapies.

## Steps toward recovery

Under interim leadership, FDA is revisiting controversial decisions. This review process aims to increase transparency and clarify scientific rationale. However, lasting change requires institutional reforms beyond temporary fixes.

## Pasteur's legacy

As Louis Pasteur noted, science is the highest expression of a nation. Restoring trust in FDA matters not just for US biomedical leadership, but for global patient access to life-saving treatments developed through rigorous science.

## Sources covering this story

- https://fortune.com/2026/07/14/fda-trust-decline-political-interference-rfk/ — 

---

_Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._
